INO-3107 shows promise in reducing surgeries for RRP patients

Published 12/02/2025, 14:10
INO-3107 shows promise in reducing surgeries for RRP patients

PLYMOUTH MEETING, Pa. - INOVIO (NASDAQ: INO), a biotechnology company with a market capitalization of approximately $69 million, has announced positive results from a Phase 1/2 clinical trial of INO-3107, its investigational DNA medicine for treating recurrent respiratory papillomatosis (RRP). Published in Nature Communications, the trial data indicates that INO-3107 may reduce the need for surgeries in patients with RRP. According to InvestingPro data, while the company maintains a strong liquidity position with a current ratio of 3.88, it faces significant financial challenges with rapidly declining revenues.

The study involved 32 patients who, prior to treatment, required multiple surgeries to manage their condition. Post-treatment with INO-3107, 81% of the participants needed fewer surgical interventions compared to the previous year. Notably, 26 patients experienced a reduction in the number of surgeries, with 9 patients not requiring any further surgical procedures during or after the treatment period. The treatment was well-tolerated, with the most common adverse events being injection site pain and fatigue, none exceeding Grade 2 severity. For investors seeking deeper insights into INOVIO’s financial health and growth prospects, InvestingPro offers comprehensive analysis with 12 additional ProTips and detailed metrics.

INO-3107 works by inducing T cell responses against HPV-6 and HPV-11, the viruses responsible for RRP, and has shown potential in preventing or slowing the growth of new papillomas. The trial’s findings suggest that the medicine can generate a strong immune response, with activated T cells present even at week 52, indicating a lasting cellular memory response.

RRP is a rare disease characterized by benign growths in the respiratory tract, which can lead to severe complications and impact the quality of life. Patients typically undergo repeated surgeries to remove these growths, which carry a risk of vocal cord damage.

INOVIO plans to submit a biologics license application for INO-3107 in mid-2025 and will seek accelerated approval from the FDA. If approved, INO-3107 would become the first DNA medicine authorized for use in the United States. The FDA has previously granted INO-3107 Orphan Drug and Breakthrough Therapy designations, acknowledging its potential significance in treating RRP. The company’s stock, which has experienced a significant 73% decline over the past year, currently trades below its InvestingPro Fair Value, suggesting potential upside for investors willing to weather the current volatility.

The company’s DNA medicines platform, which includes the investigational medical device CELLECTRA®, is designed to optimize the delivery of DNA plasmids without the need for adjuvants or lipid nanoparticles. This approach aims to produce targeted immune responses to fight diseases.

The information in this article is based on a press release statement.

In other recent news, INOVIO Pharmaceuticals has announced terms for a $30 million public stock offering, offering 10 million shares and warrants to purchase an additional 10 million shares. The biotech firm expects to close the offering soon, with Oppenheimer & Co. Inc. and Citizens JMP serving as joint book-running managers. These developments come on the heels of INOVIO’s recent third-quarter financial report, which revealed operational expenses of $27.3 million and remaining cash reserves of $84.8 million.

In the wake of these financial results, analyst firms Oppenheimer, H.C. Wainwright, and RBC Capital Markets have adjusted their price targets for INOVIO. Despite the adjustments, Oppenheimer retains an Outperform rating for the company, expressing optimism for its advancements outside the United States and new immunological data. H.C. Wainwright, however, maintains a Neutral rating due to the presence of a competing gene therapy for Recurrent Respiratory Papillomatosis (RRP), which has influenced their valuation of INOVIO. RBC Capital also retains a Sector Perform rating, citing the company’s focus on key projects amidst financial constraints.

In addition to these financial developments, INOVIO is making progress with its lead product candidate, INO-3107, for treating recurrent respiratory papillomatosis (RRP). The company is preparing for a Biologics License Application (BLA) submission by mid-2025. Despite facing competition, INOVIO’s executives are confident in INO-3107’s market potential and are developing strategies for successful market entry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.